
Eli Lilly’s Emgality shows positive Phase 3 results in treatment of migraine
pharmafile | May 8, 2019 | News story | Research and Development | Eli Lilly, Emgality, cluster headache, headache, migraine, pharma
Eli Lilly has announced positive results from the Phase 3 EVOLVE-1 and EVOLVE-2 trials looking into Emgality (galcanezumab-gnlm) for the treatment of episodic migraine.
The drug was found to reduce the number of migraine headache days patients experienced each month, in comparison to placebo.
Patients – who were categorised as either low-frequency (four to seven migraine days a month) or high-frequency (eight to 14 monthly migraine days a month) – were given either 120mg or 240mg doses of Lilly’s Emgality.
Both doses were found to reduce the number of migraine days in both the low-frequency and high-frequency subgroups in comparison to placebo.
Lilly Bio-Medicines Neurology Development vice-president Gudarz Davar commented: “Migraine causes people to suffer from substantial pain and impairment, no matter how frequently they occur.”
“These collective analyses of more than 1,700 patients with episodic migraine from our Phase 3 Emgality programme reflect our continued commitment to aid people living with this serious neurologic disorder.”
The FDA is also currently reviewing the monoclonal antibody, which specifically targets calcitonin gene-related peptide (CGRP), as a preventative treatment of episodic cluster headache in adults.
Louis Goss
Related Content

Teva announces positive results from trial of AJOVY for migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …

Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …






